Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 27,433

Document Document Title
WO/2021/089736A1
The present invention relates to the treatment of muscular diseases.  
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/092166A1
Methods of treating subjects having G4C2 dipeptide repeat expansion in the gene C90RF72, including subjects having amyotrophic lateral sclerosis or frontotemporal degeneration (ALS/FTD), are provided. Compounds directed at reducing the t...  
WO/2021/091381A1
A pharmaceutical liquid composition is provided comprising a solution of a physiologically acceptable salt of 4-phenylbutyric acid, preferably the sodium salt of 4-phenylbutyric acid, in an aqueous medium at a concentration of at least 1...  
WO/2021/091855A1
Methods and compositions for treating aging-related diseases as well as muscle recovery, prevention of muscle degeneration, and maintenance of muscle are described. The compositions used in the methods include blood plasma and blood plas...  
WO/2021/085640A1
The present invention provides an agent that is for inhibiting the decrease of muscle mass and that is characterized by containing a ghrelin receptor agonist as an active ingredient and by being used for administration during a fasting p...  
WO/2021/087039A1
Composition containing egg yolk powder and a second muscle enhancing product for use in enhancing muscle growth and slowing muscle degeneration in mammals are provided. Embodiments of the present invention are generally related to muscle...  
WO/2021/086172A1
The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.  
WO/2021/085291A1
The purpose of the present invention is to provide: a composition for TGR5 activation, said composition comprising, as an active ingredient, a substance that has an effect of activating TGR5 and shows a high selectivity for TGR5; and a m...  
WO/2021/086101A1
The present invention relates to a use of a novel compound, for preventing, improving or treating amyotrophic lateral sclerosis (ALS). The present inventors have found that SOD1 aggregation is one of the important causes of ALS, and have...  
WO/2021/086017A1
Ginsenoside Rf, a ginsenoside composition comprising ginsenoside Rf, or a mixture of any one or more thereof, of the present invention, promotes the expression of a myosin heavy chain, which is a muscle differentiation marker, regulates ...  
WO/2021/086190A1
The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.  
WO/2021/079795A1
The purpose of the present invention is to provide a novel transdermal patch having superior medicine-retaining properties and excellent adhesiveness to skin. One example of the present invention is a layered transdermal patch A compri...  
WO/2021/081345A1
The present invention includes a bi-peptide, a method of making, and a method using the bi-peptide to treat a disease or condition, wherein the bi-peptide comprises the formula: peptide 1n - linkern - peptide 2n, or peptide 2n - linkern ...  
WO/2021/080013A1
Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and metho...  
WO/2021/079987A1
The present invention relates to a muscle quality improvement agent that contains a γ-glutamyl peptide. This invention makes it possible to provide a muscle quality improvement agent that can prevent a decrease in muscle quality or impr...  
WO/2021/081272A1
Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).  
WO/2021/081293A1
This invention is directed to novel compositions containing a source of precursors to Type I collagen, an collagenic organic acid, an aldehyde, a polyol, an aldose, esters or salts or any combinations thereof, a blend of collagenic monom...  
WO/2021/075477A1
The present invention provides a motor neuron degeneration inhibitor. The present invention relates to a motor neuron degeneration inhibitor that contains one or more compounds selected from N-[3-({2-[(cyclopropanecarbonyl)amino]imidaz...  
WO/2021/072276A1
The present invention includes methods for treating a disease or disorder that is associated with aberrant or absent dystrophin, by upregulating a brain isoform of dystrophin (e.g. purkinje and/or cortical) in a subject in need thereof. ...  
WO/2021/068802A1
Provided is an application of NADH and a salt and/or NMN thereof in the preparation of a drug or health care product for enhancing muscle or inhibiting muscle volume reduction. Provided is a drug composition or health care product compos...  
WO/2021/068884A1
Provided is a polypeptide derivative having a sequence of X-Phe-Phe-Gly-Ser-Ser-Ser-Arg, wherein the end group X is Nap or Npx, The Phes are in L configuration or D configuration simultaneously, and the rest are in L configuration, the p...  
WO/2021/072201A1
Aspects of the disclosure relate to compositions and methods for treating certain diseases associated with the presence of one or more premature stop codons in a gene, for example dominantly inherited diseases or recessively inherited di...  
WO/2021/066136A1
Provided is a novel therapeutic agent for MD which is not a drug for exon skipping and which exerts an excellent effect on patients over a broad range. The therapeutic agent for MD comprises a combination of a prostaglandin synthesis i...  
WO/2021/066078A1
[Problem] To provide a muscle tissue-regenerating agent containing fibroin protein. [Solution] This muscle tissue-regenerating agent contains modified fibroin protein.  
WO/2021/064421A1
The present invention relates to treatment of AR-related disorders by modulating the levels of AR2, which is a naturally occurring AR variant and is capable of modulating AR transcriptional activity.  
WO/2021/065697A1
[Problem] To provide a novel patch which has excellent drug retainability. [Solution] The present invention provides, as an example, a layered patch in which a release layer 1, a drug layer 2, a drug support layer 3, an adhesive layer 4,...  
WO/2021/064151A1
The present invention relates to the use of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester, optionally in combination with vitamin D3, in prevention of decline in lean muscle mass, falls with and without an injury...  
WO/2021/007453A3
The disclosure provides compositions and methods for delivering a payload to cells or tissues that express GLUT4. In some embodiments, the compositions comprise an antibody, or fragment or derivative thereof, that specifically binds to g...  
WO/2021/065661A1
The purpose of the present invention is to provide: a composition for the suppression of a decrease in muscle mass, prevention of a decrease therein, maintenance thereof, recovery thereof or increase therein; a composition for the suppre...  
WO/2021/063373A1
The present invention relates to a compound represented by formula I and a stereoisomer, tautomer, solvate, polymorph thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, a preparation meth...  
WO/2021/062007A1
The present disclosure provides a method of treating mitochondrial and age-related diseases and disorders with exercised blood products. The blood products include circulating factors whose production or secretion into the blood is stimu...  
WO/2021/060884A1
According to an embodiment of the present invention, provided is a composition for preventing or treating sarcopenia containing a non-natural amino acid derivative as an active ingredient.  
WO/2021/060880A1
According to one embodiment of the present invention, provided is a composition for preventing or treating sarcopenia, containing, as an active ingredient, at least one type of unnatural amino acid selected from the group consisting of D...  
WO/2021/034984A3
Disclosed herein are methods and systems for increasing expression of Pax7, methods of activating endogenous myogenic transcription factor Pax7 in a cell, methods of differentiating a stem cell into a skeletal muscle progenitor cell, as ...  
WO/2021/060927A1
The present invention relates to a composition for alleviating, preventing or treating sarcopenia, containing, as an active ingredient, a whey protein hydrolysate, obtained by performing, on whey protein, primary hydrolysis using a Bacil...  
WO/2021/055358A1
The invention relates to composition and methods for expressing UDP-GlcNAc 2-Epimerase/ManNAc Kinase enzyme (GNE) in a living organism. In preferred embodiments, the invention relates to treating disease condition that involves use of th...  
WO/2021/054474A1
In the present invention, a disaccharide unit for synthesizing a useful sugar chain for suppressing the development of dystroglycanopathy is obtained and used to reconstitute a post-phosphoryl sugar chain. Provided are: a disaccharide ...  
WO/2021/051899A1
The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a...  
WO/2021/053243A1
A method of making an erythroid cell comprising elevated levels of a target protein or polypeptide, the method comprising: a) provision of an erythroid progenitor which is able to express the target protein or polypeptide; b) expression ...  
WO/2021/055011A1
The present invention is directed to compounds, compositions, and methods useful for modulating gene splicing. In some embodiments, modulating gene splicing increases expression of a target protein or a target functional RNA.  
WO/2021/050885A1
The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods for treating amyotrophic lateral sclerosis (ALS).  
WO/2021/047555A1
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...  
WO/2021/030766A8
Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a small molecule that promotes SMN function and/or a re...  
WO/2021/046355A1
The present disclosure describes a method for treating mitochondrial DNA depletion syndrome by administration of a therapeutic amount of a composition comprising a dinucleotide compound or a mixture thereof. Further described herein are ...  
WO/2021/044608A1
As a technique for suppressing the generation of impurities in an aqueous formulation of dantrolene or a pharmacologically acceptable salt thereof, there is provided a dantrolene aqueous formulation including dantrolene or a pharmacologi...  
WO/2021/043120A1
A compound amino acid dipeptide injection and a preparation method therefor and an application thereof. The compound amino acid dipeptide injection comprises three cavity bags spaced apart from each other and respectively filled with a b...  
WO/2021/041866A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and thei...  
WO/2021/039084A1
[Problem] To provide a sugammadex sodium injection formulation capable of suppressing fluctuations in foreign substances such as analog substances and being stably preserved for a long period of time. [Solution] An injection formulation ...  
WO/2021/039968A1
The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally ...  

Matches 1 - 50 out of 27,433